Clinical Trials Logo

Filter by:
NCT ID: NCT06438471 Recruiting - Clinical trials for Spinal Cord Injuries

Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury

Start date: July 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate safety and tolerability of multiple oral doses of EC5026 in male and female patients with neuropathic pain due to spinal cord injury. The main question it aims to answer is whether EC5026 is safe and well tolerated in SCI patients with neuropathic pain. In addition, this trial will also study the effects of EC5026 on pain. Researchers will compare EC5026 to placebo. Participants will be asked to: - Take EC5026 or placebo in a masked fashion, once daily, for 14 consecutive days. - Undergo physical exams, vital signs assessments, ECGs, and blood draws - Complete assessments of pain, sleep, functional status, and perception of change

NCT ID: NCT06437405 Recruiting - Cognitive Change Clinical Trials

Resistance Exercise Plus Vinegar Ingestion on Biomarkers in Healthy Adults

Start date: May 22, 2024
Phase: N/A
Study type: Interventional

Given its capacity to stimulate exercise-induced neuroplasticity at lower doses compared to aerobic exercise, resistance exercise has become the top-recommended rehabilitation approach for individuals with neurocognitive impairments. Despite a large body of evidence supporting its application in the context of cognition, little work has been done to investigate the role of resistance exercise in modifying the structure and function of the microbiota-gut-brain axis. Likewise, despite a general understanding of the benefits of short chain fatty acids such as acetate for the gut-brain axis, the impact of exogenous acetic acid has not been sufficiently examined in the context of the intestinal barrier. While self-reported mood disturbance responds favorably to vinegar ingestion, it is currently unknown if these effects are also associated with changes in intestinal permeability.

NCT ID: NCT06437223 Recruiting - Long COVID Clinical Trials

Study of Xiflamâ„¢ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)

Start date: March 12, 2024
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety and efficacy of Xiflam versus Placebo in patients who present with signs and symptoms of Long COVID. Xiflam (n=10) or placebo (n=5) will be administered orally once a day (QD) for 12 weeks.

NCT ID: NCT06437171 Recruiting - Food Allergy Clinical Trials

FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA

Start date: May 2024
Phase: Phase 4
Study type: Interventional

This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.

NCT ID: NCT06436924 Recruiting - Atrial Fibrillation Clinical Trials

Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Device Implant Procedural Day

Start date: May 30, 2024
Phase:
Study type: Observational

SAFE HV is an observational, prospective, multi-center, non-randomized study evaluating real-world clinical experience of centers where a single procedural physician schedules eight or more left atrial appendage occlusion (LAAO) device implant procedures in a single calendar day.

NCT ID: NCT06436846 Recruiting - Soft Tissue Sarcoma Clinical Trials

Genomic Risk in Retroperitoneal Sarcoma

Start date: March 7, 2022
Phase:
Study type: Observational

The protocol intends to explore the biology which may underlie recurrences of retroperitoneal liposarcoma. Surgery remains the only curative intent intervention for this disease. Often, tumors recur in locations within the retroperitoneum remote from the original primary tumor. This study hypothesizes that normal appearing retroperitoneal fat actually harbors underlying genetic changes which predispose to development of future liposarcoma. To accomplish this goal, retroperitoneal fat is sampled from quadrants within and remote from the primary tumor and is subsequently subjected to genetic analyses looking for such predisposing factors.

NCT ID: NCT06436703 Recruiting - Influenza, Human Clinical Trials

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

Start date: May 24, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to learn if modified RNA (modRNA) vaccines for the prevention of influenza are: - safe; and - how these vaccines produce an immune response in generally healthy adults. Immune response is the way the body protects itself against things it sees as harmful or foreign. RNA (also called ribonucleic acid) is one of two types of nucleic acid made by cells. RNA contains information that has been copied from DNA (the other type of nucleic acid). Cells make several different forms of RNA, and each form has a specific job in the cell. Many forms of RNA have functions related to making proteins. RNA is also the genetic material of some viruses instead of DNA. RNA can be made in the laboratory and used in research studies. Also called ribonucleic acid. Influenza is term used for flu illness. It is an infection caused by a virus that affects your mouth, nose, and throat. The study is seeking for participants who: - are at least 18 years of age - have not received an influenza vaccine within the last 6 months - are generally healthy This study will be divided into three sub-studies: Substudy A (SSA), Substudy B (SSB), and Substudy C (SSC). All participants, regardless of sub-study, will receive 1 dose of either of the following vaccines as an injection into their arm: - 1 of the modRNA influenza vaccines that is being studied; or - an approved influenza vaccine approved for use in their respective age group. Participants will be involved in this study for about 6 months. During this time, participants will have at least 3 clinic visits.

NCT ID: NCT06436612 Recruiting - Clinical trials for Abdominopelvic Sarcomas

Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)

Start date: May 30, 2024
Phase: Phase 2
Study type: Interventional

Recent advances in radiation treatment have allowed for higher doses per treatment to be delivered safely. This study plans to use an MRI-guided linear accelerator to deliver the radiation treatment to ensure that the radiation dose is administered to the cancerous tumor, not the vital body organs. Potential participants with a sarcoma diagnosis will be referred to Radiation Oncology during this study. If the participant is interested in participating in this study, s/he receives radiation treatment daily for 5 consecutive days except for weekends and holidays. Within 12 weeks of completing the radiation therapy, the participant will have the primary tumor surgically removed. The radiation oncology team will follow the patients for 5 years after completing radiation therapy.

NCT ID: NCT06436209 Recruiting - Healthy Volunteers Clinical Trials

Cognitive Control & the Functional Organization of the Frontal Cortex

Start date: March 27, 2024
Phase: N/A
Study type: Interventional

The goal of this basic experimental clinical trial is to understand the effect of multitasking practice on the structure of neural representations of tasks in the human lateral prefrontal cortex and control brain regions. The main question it aims to answer is: What changes in neural representational structure predict improvements in multitasking behavior due to multitasking practice? Healthy human participants will learn two independent tasks, each mapping a set of stimuli to motor responses based on different rules. Participants will be randomized to one of two interventions. Participants assigned to the multitask practice intervention (MPI) will practice multitasking the two tasks over multiple days. Those assigned to the single-task practice intervention (SPI) will instead practice each task separately while controlling for the total number of practice opportunities associated with each task across the interventions. Both before and after the practice, the ability of all participants to perform both tasks simultaneously will be behaviorally measured using a well-established psychological refractory period (PRP) paradigm, and their neural representations will be measured using functional MRI while they perform the two tasks. Researchers will then compare improvements in multitasking behavior across the two groups, as well as changes in neural representational geometry of the tasks in the lateral prefrontal cortex and control brain regions, and test whether multitasking training is associated with specific changes in neural representations in the lateral prefrontal cortex.

NCT ID: NCT06436183 Recruiting - Atopic Dermatitis Clinical Trials

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.